Shamburg News · 8-K filed Nov 18, 2026, 8:16 AM EST

Summit Therapeutics Plans Phase III HARMONi-10 Trial of Ivonescimab in Stage III NSCLC

SMMT · Summit Therapeutics Inc.

  • Other event
  • Materiality: low

On November 18, 2026, Summit Therapeutics Inc. announced the initiation of the global Phase III HARMONi-10 trial, evaluating ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer who have not progressed after platinum-based concurrent chemoradiation. The primary endpoint is progression-free survival, and global site activations are expected to begin in the fourth quarter of 2026. Ivonescimab is not approved by any regulatory authority in Summit's license territories, including the United States and Europe.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001599298-26-000094.

Written from the filing by Shamburg Markets. Figures are as reported by the company.